Telehealth provider Hims & Hers began selling a compounded pill version of Novo Nordisk’s Wegovy, prompting immediate industry and regulatory blowback. Novo has threatened litigation, calling the product an “unapproved, inauthentic” copy of its oral formulation; Hims positioned the offering as an access alternative. The move has triggered scrutiny from regulators and rival manufacturers. Legal experts say Novo’s threatened suits face hurdles because compounded products occupy a complex regulatory space, and enforcement outcomes could hinge on labeling, marketing claims and state pharmacy laws. The dispute occurs as oral GLP-1s rapidly scale, raising questions about compounding practices and intellectual property boundaries in an exploding obesity market. The episode matters for payers, clinics, and manufacturers: it could set precedent on how quickly competitors and telehealth platforms can commercialize compounded versions of hot new drugs, and whether regulators will intervene to curb mass distribution of unapproved formulations.